Greensboro, NC, United States of America

Ami M Kabadi

This inventor holds 2 USPTO granted patents and 4 published patent applications and 3 EPO patents. Top assignee: Duke University. Active years: 2020.

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.0

ph-index = 2

Forward Citations = 67(Granted Patents)


Location History:

  • Greensboro, NC (US) (2020)
  • Durham, NC (US) (2020)

Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Ami M Kabadi

Introduction

Ami M Kabadi is a prominent inventor based in Greensboro, NC (US). She has made significant contributions to the field of gene editing and regulation. With a focus on advanced technologies, her work has the potential to revolutionize genetic engineering.

Latest Patents

Ami M Kabadi holds 2 patents related to RNA-guided gene editing and gene regulation. Her latest patents involve the use of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) 9-based system. These patents disclose compositions and methods for altering gene expression and genome engineering, particularly in muscle tissues such as skeletal and cardiac muscle.

Career Highlights

Ami M Kabadi is affiliated with Duke University, where she continues her research and innovation in genetic engineering. Her work is at the forefront of scientific advancements, contributing to the understanding and application of CRISPR technology.

Collaborations

Ami collaborates with notable colleagues, including Charles A Gersbach and Isaac B Hilton. These partnerships enhance her research capabilities and broaden the impact of her innovations.

Conclusion

Ami M Kabadi is a trailblazer in the field of gene editing, with her patents paving the way for future advancements in genetic engineering. Her contributions are vital to the ongoing evolution of biotechnology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…